Acute Vulvovaginal Candidiasis Market Size is valued at USD 339.50 Million in 2024 and is predicted to reach USD 507.32 Million by the year 2034 at a CAGR of 4.2% during the forecast period for 2025-2034.
The acute vulvovaginal candidiasis market includes the development of several treatments and medications for the treatment of acute vulvovaginal candidiasis. The candida albicans fungus causes acute vulvovaginal candidiasis (VVC), which is also known as vaginal thrush. The illness is caused by a fungal overgrowth, which manifests as abnormal vaginal discharge, acute discomfort during intercourse, and vaginal itching. Approximately 75 % of women are projected to be affected by the VVC at some point in their lives. Although the majority of VVC cases are small, the infection can develop seriously in some women, resulting in swelling, cracks in the vaginal wall, and redness.
Furthermore, the demand for acute vulvovaginal candidiasis therapy is increasing in lockstep with the global disease burden, indicating a growing desire for better treatment options and a rise in the number of hospital-acquired infections. The development of new antifungal drugs, an increase in healthcare spending, and the growth of healthcare infrastructure are also driving the global acute vulvovaginal candidiasis treatment market. Furthermore, market participants compete for clearance to manufacture their products by submitting new drug applications (NDAs) to regulatory organizations. As a result of this factor, the global acute vulvovaginal candidiasis market is expected to grow.
However, the global acute vulvovaginal candidiasis therapy market is predicted to be hampered by the COVID-19 pandemic over the forecast period. According to the Indian Journal of Medical Sciences, on June 6, 2020, the COVID-19 pandemic has impeded the conduct of clinical trials due to a lack of trial site employees, travel restrictions, experimental product supply, and other problems. The development of new therapeutics for acute vulvovaginal candidiasis is hampered by these roadblocks. Infection with Candida albicans is becoming increasingly common among patients in intensive care units. Furthermore, prominent firms have suspended operations in various places due to the lockdown and social distancing practices.
The Acute Vulvovaginal Candidiasis Treatment Market is segmented based on Drug Types, Route of Administration, and Distribution Channels. Based on Drug Types, the market is bifurcated as Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, and Other Drug Types. Based on Route of Administration, the market is categorized into Oral, Intravenous, and Topical. Based on Distribution Channels, the market is segmented as Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
Clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole, and others are the medication types that make up the global acute vulvovaginal candidiasis therapy market. Due to its high efficiency and widespread use in the treatment of acute vulvovaginal candidiasis, the clotrimazole segment is likely to dominate the global market throughout the projection period.
The global acute vulvovaginal candidiasis treatment market can be divided into hospital pharmacies, retail pharmacies, internet pharmacies, and other distribution channels. As a result of the huge number of patients treated in hospitals, the hospital pharmacies segment is anticipated to hold a significant portion of the global acute vulvovaginal candidiasis treatment market by 2031.
The Asia Pacific acute vulvovaginal candidiasis market is likely to grow significantly over the forecast period. The global acute vulvovaginal candidiasis market is being boosted by raising awareness of this ailment among rural women, as well as Indian government programmes such as 'Swachhta, Swasthya, and Suvidha' to promote the cleanliness of poor women. Furthermore, developing economies such as China and Japan are expected to contribute to market expansion in the Asia Pacific as a result of improved healthcare infrastructure, an increase in the number of insurance payers, economic growth, the development of the private healthcare sector, and an increase in education and awareness. However, North America is also expected to rise fast over the forecast period in the worldwide acute vulvovaginal candidiasis market.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 339.50 Million |
|
Revenue Forecast In 2034 |
USD 507.32 Million |
|
Growth Rate CAGR |
CAGR of 4.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Type, Route of Administration, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; Japan; India; South Korea; South East Asia |
|
Competitive Landscape |
Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Padagis LLC, ProFem GmbH, Amplyx Pharmaceuticals Inc., MethylGene Inc., Ferrer Internacional S.A., Pfizer, Inc., and Other Prominent Players |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Acute Vulvovaginal Candidiasis Treatment Market Snapshot
Chapter 4. Global Acute Vulvovaginal Candidiasis Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Types Estimates & Trend Analysis
5.1. By Drug Types & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Types:
5.2.1. Clotrimazole
5.2.2. Nystatin
5.2.3. Fluconazole
5.2.4. Ketoconazole
5.2.5. Terbinafine
5.2.6. Terconazole
5.2.7. Other Drug Types
Chapter 6. Market Segmentation 2: By Route of Administration Estimates & Trend Analysis
6.1. By Route of Administration & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administration:
6.2.1. On-Cloud
6.2.2. Web-Based
6.2.3. On-Premises
Chapter 7. Market Segmentation 3: By Distribution Channels Estimates & Trend Analysis
7.1. By Distribution Channels & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Distribution Channels:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. Acute Vulvovaginal Candidiasis Treatment Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts By Drug Types, 2021-2034
8.1.2. North America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2021-2034
8.1.3. North America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
8.1.4. North America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Drug Types, 2021-2034
8.2.2. Europe Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Route of Administration, 2021-2034
8.2.3. Europe Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
8.2.4. Europe Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Drug Types, 2021-2034
8.3.2. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Route of Administration, 2021-2034
8.3.3. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
8.3.4. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Drug Types, 2021-2034
8.4.2. Latin America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Route of Administration, 2021-2034
8.4.3. Latin America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
8.4.4. Latin America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Drug Types, 2021-2034
8.5.2. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Route of Administration, 2021-2034
8.5.3. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
8.5.4. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Mycovia Pharmaceuticals, Inc.
9.2.2. Scynexis, Inc.
9.2.3. Basilea Pharmaceutica Ltd.
9.2.4. Astellas Pharma Inc.
9.2.5. Grupo Ferrer Internacional, S.A.
9.2.6. Pacgen Life Science Corporation
9.2.7. NovaDigm Therapeutics, Inc.
9.2.8. Cidara Therapeutics, Inc.
9.2.9. Padagis LLC
9.2.10. ProFem GmbH
9.2.11. Amplyx Pharmaceuticals Inc.
9.2.12. MethylGene Inc.
9.2.13. Ferrer Internacional S.A.
9.2.14. Pfizer, Inc.
9.2.15. Other Prominent Players
By Drug Type-
By Route of Administration -
By Distribution Channels -
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
